Dr. McKinney Discusses the Watch-and-Wait Approach in MCL

Matthew S. McKinney, MD
Published: Wednesday, May 29, 2019



Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses the watch-and-wait approach in mantle cell lymphoma (MCL).

About 10% to 15% of patients with newly diagnosed MCL are appropriate for active surveillance, McKinney says. First, a physician should check for symptoms that indicate a need for immediate treatment. Identifying molecular markers in a patient is also crucial, as p53 mutations and blastoid variant histology represent an aggressive biology.

Beyond that, McKinney adds, physicians should rely on clinical judgement based on pathologic markers like SOX11. Data show that patients do well with the watch-and-wait approach if they have indolent disease. Effectively utilizing this strategy can save the patient months or even years from potentially toxic treatment, says McKinney.
SELECTED
LANGUAGE


Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses the watch-and-wait approach in mantle cell lymphoma (MCL).

About 10% to 15% of patients with newly diagnosed MCL are appropriate for active surveillance, McKinney says. First, a physician should check for symptoms that indicate a need for immediate treatment. Identifying molecular markers in a patient is also crucial, as p53 mutations and blastoid variant histology represent an aggressive biology.

Beyond that, McKinney adds, physicians should rely on clinical judgement based on pathologic markers like SOX11. Data show that patients do well with the watch-and-wait approach if they have indolent disease. Effectively utilizing this strategy can save the patient months or even years from potentially toxic treatment, says McKinney.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x